2018 was a decent, not spectacular, year for CROs. We witnessed year-over-year revenue growth from all the major/public CROs. Yet, the major publicly traded CROs took a pause, along with the rest of the market. Remember, the S&P 500 fell by ~6% in 2018, so the fact that most of the public CROs managed to gain, is a win.
The biopharmaceutical fundamentals stayed intact and CROs were able to take advantage. The publisher's report gives quantitative insight into the perpetual question: “What is the size of the CRO market?” The data provide a thorough, rational perspective for clinical development services segmented by phase, geography, and service line.
ISR utilizes both publicly available information and data obtained through our syndicated primary market research efforts.
Estimated R&D expenditures through 2023
Projected spending on development, Phase I-IV development, and outsourced Phase I-IV development through 2023, segmented by sponsor type:
- Large pharma – large molecule
- Large pharma – small molecule
- Non-large pharma – large molecule
- Non-large pharma – small molecule
Spending on CRO services segmented by:
- Phase I-IV
- Overall Market Size and Growth
- 2019 Geographic Assessment
- 2019 Service-line Assessment
- 2019 Development Phase I-IV Assessment
- 2018-2023 CRO Market Model
- 2018-2023 CRO Market Model – Growth Rates
- 2019 Public CRO Market Share